Frequently Asked Questions
Q: How does high-throughput screening for AAV media impact timelines for IND submissions?
High-throughput screening significantly shortens the process development phase by rapidly identifying optimal media and supplement conditions. This acceleration provides sufficient, high-quality vector for IND-enabling toxicology studies faster, supporting an 18-24 month timeline to IND. This data is foundational for the CMC section of submissions to global bodies like the FDA and under ICH guidelines.
Q: Can a single media formulation be used for all AAV serotypes?
No, a universal formulation is not optimal. Different AAV serotypes, such as AAV8 and AAV9, exhibit distinct production kinetics and sensitivities to media components. A tailored screening approach is necessary to define a formulation that maximizes capsid assembly and packaging efficiency for the specific serotype and transgene construct.
Q: What is the relationship between media selection and final AAV vector quality attributes?
Media components directly influence key quality attributes (CQAs) beyond simple vector titer. The formulation can affect the ratio of full to empty capsids, aggregation profiles, and the presence of process-related impurities. A robust screening process evaluates these CQAs to select for conditions that produce a potent and stable final product.
High-Throughput Screening for AAV Media and Supplement Optimization
Proven Intelligence in AAV Process Development.
The transition from research-grade to clinical-scale AAV production requires a systematic approach to process optimization. A central variable controlling the productivity of AAV scalable suspension platforms is the composition of the cell culture media and associated supplements. An inadequately optimized formulation can limit vector yields, compromise quality, and create significant bottlenecks for generating material required for IND-enabling studies.
Franklin Biolabs utilizes high-throughput screening (HTS) methodologies to de-risk and accelerate this upstream development step. By moving beyond traditional, low-throughput DOE studies, our process development teams can systematically evaluate a vast matrix of media components, feed strategies, and supplements in parallel. This data-driven process identifies formulations that maximize productivity for specific AAV serotypes and constructs.
Data-Driven Formulation Design
Our approach is built on a foundation of deep vector biology expertise. The team’s historical work informs our screening strategies, recognizing that achieving high functional titers is a primary objective for therapeutic efficacy. For instance, developing vectors for challenging applications like airway-directed passive immunization requires maximizing vector potency to achieve a protective effect (PMID: 25209558). This level of optimization is only achievable through comprehensive screening.
The process involves:
-
Automated Liquid Handling: Robotic platforms enable precise, parallel preparation of hundreds of unique media conditions in microplate formats, reducing manual error and increasing throughput.
-
Multi-Parametric Readouts: Screening is not limited to vector titer alone. We integrate analytics to assess key quality attributes like the full-to-empty capsid ratio and vector integrity early in the process.
-
Serotype-Specific Platforms: We have developed baseline media platforms for clinically relevant serotypes, including AAV1, AAV8, and AAV9, which serve as a starting point for further refinement.
This mirrors the rigor required in downstream analytics, where optimized protocols are necessary to accurately quantify biological activity and ensure reliable data (PMID: 18287636). A robust upstream process generates higher quality material that behaves more predictably in subsequent analytical and in vivo characterization. The knowledge gained from our work with partners like Moderna on LNP delivery systems further informs our understanding of complex biologic formulation.
“Wonderful services. Excellent team to work with. Vast knowledge in all aspects of vector production and analytics.”
– Biotech Partner
The output of this screening is a validated, scalable media and feed strategy ready for implementation in single-use bioreactors from 2L to 500L+. This work is performed within our >100,000 sq ft facilities by the same scientific leadership team whose track record includes a 100% successful IND rate since 2019, established prior to the formal launch of Franklin Biolabs in 2024. For a broader overview of our capabilities, see our main page on Large-Scale AAV Manufacturing and Process Development.
Our integrated approach to vector manufacturing and process development is detailed in our recent webinar.
